Thera-SAbDab

LAMPALIZUMAB

> Structural Summary

Therapeutic	Lampalizumab
Target	CFD
Heavy Chain	EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS
Light Chain	DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK
100% seqID Fv Structure	4d9q [Fvs: ED, HL], 4d9r [Fvs: ED, HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4d9q [Fvs: ED, HL]
100% seqID Structure	4d9r [Fvs: ED, HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Fab
Isotype	G1
Highest Clinical Trial (Aug '24)	Phase-III
Estimated Status (Aug '24)	Discontinued
Recorded Developmental Technology
INN Year Proposed	2012
INN Year Recommended	2013
Companies Involved	Tanox, Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Dry age-related macular degeneration
Notes	Erroneously dropped during Feb '22 update. Readded August '22.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy